$ cat ./records/gates-foundation-funds-menafrivac-meningitis-vaccine-for-sub-saha-2001.txt
Gates Foundation Funds MenAfriVac Meningitis Vaccine for Sub-Saharan Africa
[RECORD.TXT] · cat --full
The Gates Foundation awarded $70 million over ten years to establish the Meningitis Vaccine Project — a joint venture of PATH and WHO — to develop, license, and introduce a low-cost Group A meningococcal conjugate vaccine (MenAfriVac) specifically for the sub-Saharan meningitis belt. The vaccine was introduced in Burkina Faso in 2010 at $0.50 per dose and was the first vaccine manufactured specifically for Africa. By 2016, more than 260 million people across 21 African countries had been vaccinated, virtually eliminating epidemic Group A meningitis from the continent.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Leads Global Measles and Rubella Elimination Initiative
Next →
Granted $1 million to IRC, Mercy Corps, and Save the Children for Afghan refugee relief
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.